Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-2 adjuvant camizestrant versus standard endocrine therapy in ER-positive/HER2-negative early breast cancer
CTR20233662Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camizestrant in breast cancer, sponsored by AstraZeneca. Started Apr 2024; status: active.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233662.